Donna Curtis1, Mariangeli F Ning1, Carl Armon2, Shaobing Li1, Adriana Weinberg3. 1. University of Colorado Denver, 12700 E 19th Avenue, Room 11126, Aurora, CO 80045, USA. 2. Children's Hospital Colorado, 13123 E 16th Avenue, B055, Aurora, CO 80045, USA. 3. University of Colorado Denver, 12700 E 19th Avenue, Room 11126, Aurora, CO 80045, USA. Electronic address: Adriana.Weinberg@ucdenver.edu.
Abstract
OBJECTIVES: HIV-infected children have poor responses to inactivated influenza vaccines. Live vaccines (LAIVs) are highly efficacious in children, but they are not used in HIV-infected children du e to limited information. We investigated the safety, immunogenicity and viral shedding of LAIV4 in HIV-infected compared with uninfected children. DESIGN: Forty-six HIV-infected and 56 uninfected children 2 to 25 years old, who had been previously vaccinated against influenza, consented to receive a single dose of LAIV4. All grade adverse events (AEs) were recorded in the first month post-vaccination and serious AEs (SAEs) throughout the influenza season. Nasopharyngeal swabs for influenza PCR and IgA ELISA and blood for hemagglutination inhibition antibody (HAI) measurements were collected at entry, 2-5, 7-10 and 21-28 days post-vaccination. RESULTS: The HIV-infected subjects had median CD4+ cells of 649 cells/μL and plasma HIV RNA of 20 copies/mL. AEs were similar in the two groups. There were no vaccine-related SAEs. Shedding of ≥1 vaccine virus was detected in 67% HIV-infected and 50% uninfected participants (p=0.14). HAI titers did not appreciably change, but mucosal IgA antibodies significantly increased post-vaccination in both groups. High baseline HAI and IgA antibody concentrations were associated with decreased viral shedding in controls, but not in HIV-infected subjects. Similar proportions of HIV-infected vaccinees and controls reported influenza-like illnesses (12% and 6%) throughout the season. CONCLUSIONS: LAIV4 was equally safe and immunogenic and caused similar viral shedding in HIV-infected and uninfected children. A correlate of protection against vaccine viral shedding was not identified in HIV-infected participants, although both circulating and mucosal antibodies correlated with protection in controls.
OBJECTIVES:HIV-infectedchildren have poor responses to inactivated influenza vaccines. Live vaccines (LAIVs) are highly efficacious in children, but they are not used in HIV-infectedchildren du e to limited information. We investigated the safety, immunogenicity and viral shedding of LAIV4 in HIV-infected compared with uninfected children. DESIGN: Forty-six HIV-infected and 56 uninfected children 2 to 25 years old, who had been previously vaccinated against influenza, consented to receive a single dose of LAIV4. All grade adverse events (AEs) were recorded in the first month post-vaccination and serious AEs (SAEs) throughout the influenza season. Nasopharyngeal swabs for influenza PCR and IgA ELISA and blood for hemagglutination inhibition antibody (HAI) measurements were collected at entry, 2-5, 7-10 and 21-28 days post-vaccination. RESULTS: The HIV-infected subjects had median CD4+ cells of 649 cells/μL and plasma HIV RNA of 20 copies/mL. AEs were similar in the two groups. There were no vaccine-related SAEs. Shedding of ≥1 vaccine virus was detected in 67% HIV-infected and 50% uninfected participants (p=0.14). HAI titers did not appreciably change, but mucosal IgA antibodies significantly increased post-vaccination in both groups. High baseline HAI and IgA antibody concentrations were associated with decreased viral shedding in controls, but not in HIV-infected subjects. Similar proportions of HIV-infected vaccinees and controls reported influenza-like illnesses (12% and 6%) throughout the season. CONCLUSIONS:LAIV4 was equally safe and immunogenic and caused similar viral shedding in HIV-infected and uninfected children. A correlate of protection against vaccine viral shedding was not identified in HIV-infectedparticipants, although both circulating and mucosal antibodies correlated with protection in controls.
Authors: Benjamin B Lindsey; Ya Jankey Jagne; Edwin P Armitage; Anika Singanayagam; Hadijatou J Sallah; Sainabou Drammeh; Elina Senghore; Nuredin I Mohammed; David Jeffries; Katja Höschler; John S Tregoning; Adam Meijer; Ed Clarke; Tao Dong; Wendy Barclay; Beate Kampmann; Thushan I de Silva Journal: Lancet Respir Med Date: 2019-06-21 Impact factor: 30.700
Authors: Adriana Weinberg; Donna Curtis; Mariangeli Freitas Ning; David Jeremy Claypool; Emilie Jalbert; Julie Patterson; Daniel N Frank; Diana Ir; Carl Armon Journal: Front Immunol Date: 2016-04-15 Impact factor: 7.561
Authors: Marta C Nunes; Adriana Weinberg; Clare L Cutland; Stephanie Jones; David Wang; Bonnie Dighero-Kemp; Min Z Levine; Niteen Wairagkar; Shabir A Madhi Journal: PLoS One Date: 2018-12-31 Impact factor: 3.240